Detalhe da pesquisa
1.
Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.
Eur Neurol
; 77(3-4): 130-136, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28052269
2.
High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions.
Patient
; 14(2): 241-248, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32975737
3.
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Ann Clin Transl Neurol
; 8(2): 385-394, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33369288
4.
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
Mult Scler Relat Disord
; 45: 102402, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32711297
5.
Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry.
Neurology
; 95(8): e1060-e1070, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32482845